Siegfried successfully places public hybrid bond

(SIX/SFZN) Siegfried Holding AG today successfully placed a subordinated public hybrid bond in the amount of CHF 100 million. The proceeds are used to finance the acquisition of BASF’s pharmaceutical supply business. The hybrid bond offers investors an initial coupon of 3.50% p.a. and will be listed on the SIX Swiss Exchange. The instrument is perpetual in nature with an initial option to redeem (call date) after 5 years. The hybrid bond is ranking pari-passu with the privately placed CHF 60 million hybrid convertible bond with RAG-Stiftung Beteiligungsgesellschaft mbH, which was issued by Siegfried on 29 September 2015. 

The successful placement of the public hybrid bond marks the completion of refinancing the acquisition of BASF’s pharmaceutical supply business. 

"The broad demand for the hybrid bond underpins investors’ interest in Siegfried. Now that the financing of the acquisition has been completed, we focus on integrating the acquired business and on realizing the respective value creation potential“, highlights Dr. Rudolf Hanko, CEO of Siegfried Group.

The hybrid bond was primarily placed amongst Swiss investors under the lead of UBS Investment Bank and Zürcher Kantonalbank. 

» Media Release (PDF) 

For further information:

Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch

About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.

Disclaimer
This communication contains certain forward-looking statements. Such statements are based on assumptions and expectations which could prove incorrect. They should be treated with appropriate caution because they naturally involve known and unknown risks, uncertainties and other factors which could mean that the actual results, financial situation, development or performance of Siegfried Holding AG or the Siegfried Group are materially different from those explicitly or implicitly assumed in these statements. 

The purpose of this document is to inform investors in Siegfried Holding AG and the public about the closing of the acquisition of significant elements of the pharmaceutical supply business of BASF and connected three production sites. This document does not constitute an offer or a solicitation to exchange, buy or subscribe to securities in any jurisdiction, nor does it constitute an offering prospectus as defined by Art. 652a or Art. 1156 of the Swiss Code of Obligations or a listing prospectus as defined by the listing rules of the SIX Swiss Exchange.

This document is available in German and English. The German version is binding. 

Contact:

Siegfried AG
Peter A. Gehler
Chief Communication Officer
Untere Bruehlstrasse 4
4800 Zofingen
Switzerland

Phone +41 62 746 1148
peter.gehler@siegfried.ch

to the top to top

Can't find the information
you are looking for?
Contact us

Siegfried AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

Phone: +41 62 746 1111
Fax: +41 62 746 1202
info@siegfried.ch